Subhan Mohammed
Pulmonary Disease · Chillicothe, OHNPI 1760865869
Payments from drug & device makers
Across 99 payments — averaging $80.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Sanofi$655
- Regeneron Healthcare Solutions, Inc.$429
- Takeda Pharmaceuticals U.S.A., Inc.$183
- United Therapeutics Corporation$173
- AstraZeneca$130
- plus $631 from 15 others
What the payments were for
- Travel & lodging$1,68021%
- Food & beverage$2,07526%
- Education$4,19553%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $5,747 |
| Sanofi | 25 | $655 |
| Regeneron Healthcare Solutions, Inc. | 14 | $429 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $183 |
| United Therapeutics Corporation | 4 | $173 |
| AstraZeneca | 7 | $130 |
| Insmed, Inc. | 6 | $112 |
| Inspire Medical Systems, Inc. | 4 | $95 |
| GSK | 5 | $86 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Pulmonx Corporation | 2 | $45 |
| Mylan Specialty L.p. | 2 | $33 |
| Amgen | 2 | $32 |
| Verona Pharma, Inc. | 1 | $26 |
| Harmony Biosciences LLC | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Boston Scientific | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
| Itamar Medical Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,650
- DUPIXENT$288
How this compares
$7,950 in reported general payments places this provider in the 70th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 90 | $355,615 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 216 | $161,958 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 194 | $128,514 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $28,512 |
| Spiriva RespimatTiotropium Bromide | 30 | $19,436 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $18,913 |
| Advair HfaFluticasone Propion/Salmeterol | 41 | $16,578 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $13,049 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 89 | $9,931 |
| DuleraMometasone/Formoterol | 18 | $7,163 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 270 | $6,870 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $3,113 |
| Ventolin HfaAlbuterol Sulfate | 38 | $2,061 |
| Roflumilast | 16 | $1,885 |
| Azithromycin | 73 | $460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $86 | $180,871248 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $130 | $141,563240 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $17 | $47,94884 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Chillicothe
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Leslie TolleCleveland$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.